Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
47 studies found for:    Open Studies | "Unrelated Donors"
Show Display Options
Rank Status Study
21 Recruiting TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID
Conditions: Primary Immune Deficiency Disorder;   Hematopoietic Stem Cell Transplantation
Intervention: Other: Biological: TCR alfa beta T cell depletion
22 Recruiting Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients
Condition: Hematologic Neoplasms
Intervention: Procedure: Allogeneic (Allo) hematopoietic stem cell transplantation
23 Recruiting Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency
Condition: DOCK8 Deficiency
Interventions: Procedure: Reduced-intensity hematopoietic stem cell;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Busulfan (Busulfex)
24 Recruiting Combined Cord Blood Transplant
Conditions: Acute Leukemia;   Immune Deficiency Disorder;   Congenital Hematological Disorder;   Metabolism Disorder;   Aplastic Anemia;   Myelodysplastic Syndromes;   Chronic Leukemia;   Lymphoma;   Multiple Myeloma;   Solid Tumor
Interventions: Radiation: Total Body Irradiation 1200 cGy;   Radiation: Total Body Irradiation 200 cGy;   Drug: Cyclophosphamide;   Drug: Mesna;   Procedure: Cord Blood Infusion;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Melphalan
25 Recruiting Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC
Conditions: Leukemia;   Inborn Errors of Metabolism;   Bone Marrow Failure Syndromes;   Immunodeficiencies;   Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome
Intervention: Device: Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)
26 Available Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC
Conditions: Leukemia;   Bone Marrow Failure Syndrome;   Immunodeficiencies
Intervention: Device: Apha/beta T and CD19+ cell depletion using CliniMACS device
27 Recruiting Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
Conditions: Graft vs Host Disease;   Hematologic Neoplasms;   Non-Neoplastic Hematologic and Lymphocytic Disorder
Interventions: Drug: Vorinostat;   Drug: Tacrolimus;   Drug: Methotrexate
28 Recruiting UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Conditions: Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia/Lymphoma;   Burkitt's Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Relapsed Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-cell Lymphoma;   Prolymphocytic Leukemia;   Bone Marrow Failure Syndromes;   Myeloproliferative Neoplasms/Myelofibrosis;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Leukemia or MDS in Aplasia;   Relapsed T-Cell Lymphoma;   Relapsed Multiple Myeloma;   Plasma Cell Leukemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: MMF;   Drug: Sirolimus;   Radiation: TBI;   Biological: Umbilical cord blood cell infusion;   Biological: ATG
29 Recruiting Alpha/Beta T and CD19+ Depleted Peripheral Stem Cells for Patients With Primary Immunodeficiencies
Conditions: Immunodeficiencies;   Immune Dysregulation Syndromes
Intervention: Device: Apha/beta T and CD19+ cell depletion using CliniMACS device
30 Recruiting Donor Stem Cell Transplantation for Congenital Immunodeficiencies
Condition: Inherited Immune Deficiencies
Interventions: Drug: Fludarabine;   Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine;   Drug: Sirolimus or equivalent based on response;   Drug: Granulocyte Colony Stimulating Factor (G-CSF);   Other: hematopoietic progenitor cells
31 Recruiting Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
Condition: Acute Myeloid Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Clofarabine;   Drug: Cyclosporine;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Radiation: Total-Body Irradiation
32 Recruiting Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression
Condition: Graft Versus Host Disease
Intervention: Drug: Tacrolimus and MMF.
33 Recruiting Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Conditions: Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Non-hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Other: Haploidentical Stem Cell Transplantation
34 Recruiting NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
Conditions: Severe Aplastic Anemia;   Aplastic Anemia;   Bone Marrow Failure;   Immunosuppression
Interventions: Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
35 Recruiting Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) <= 60y. After First CR
Condition: Leukemia, Myeloid, Acute
Interventions: Biological: Human Stem Cell Transplantation;   Drug: Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
36 Recruiting HCT Versus CT in Elderly AML
Condition: Acute Myeloid Leukemia
Interventions: Procedure: hematopoietic cell transplantation;   Drug: Non-Transplant treatment approach for consolidation
37 Recruiting Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
Conditions: Leukemia;   Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Severe Aplastic Anemia;   Allogeneic Transplant
Intervention: Drug: Cyclophosphamide
38 Not yet recruiting High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
Conditions: Acute Leukemia;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Myelodysplastic Syndrome
Interventions: Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
39 Recruiting Evaluation of 3 Different Doses of IV Busulfan
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia
Interventions: Drug: BX2;   Drug: BX3;   Drug: BX4
40 Recruiting CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Conditions: Leukemia;   Lymphoma;   Bone Marrow Failure;   Immunodeficiencies;   Histiocytosis;   Sickle Cell Disease;   Beta Thalassemia;   Inborn Errors of Metabolism
Interventions: Drug: Full Intensity with TBI;   Drug: Full Intensity;   Drug: Reduced Intensity;   Drug: Reduced Intensity (Fanconi)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-47) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.